Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus DYAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus DYAZIDE.
ATENOLOL AND CHLORTHALIDONE vs DYAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
1 tablet (atenolol 50 mg/chlorthalidone 25 mg) orally once daily. May be increased to 2 tablets once daily.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
None Documented
None Documented
Atenolol: 6-7 hours (prolonged to 14-27 hours in severe renal impairment); Chlorthalidone: 40-60 hours (allows once-daily dosing).
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Atenolol: ~50% eliminated unchanged in urine; Chlorthalidone: ~50-70% eliminated unchanged in urine, remainder as metabolites via renal and biliary routes (<10% fecal).
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic